← Back to Screener
Cel-Sci Corporation (CVM)
Price$1.48
Value ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-90.77%
Price vs S&P 500 (4W)-37.43%
VGM Score27.72
Market Capitalization$22.32M
All Metrics
Book Value / Share (Quarterly)$0.81
P/TBV (Annual)4.64x
Cash Flow / Share (Quarterly)$-1.96
Price vs S&P 500 (YTD)-81.66%
Net Profit Margin (TTM)-5445.76%
EPS (TTM)$-3.58
10-Day Avg Trading Volume0.54M
EPS Excl Extra (TTM)$-3.58
EPS (Annual)$-21.72
ROI (Annual)-129.11%
Net Profit Margin (5Y Avg)-8345.71%
Cash / Share (Quarterly)$0.22
ROA (Last FY)-105.46%
EBITD / Share (TTM)$-2.68
ROE (5Y Avg)-201.32%
Operating Margin (TTM)-5218.40%
Cash Flow / Share (Annual)$-2.14
P/B Ratio3.25x
P/B Ratio (Quarterly)3.95x
EV / Revenue (TTM)48.82x
Net Interest Coverage (TTM)-46.67x
ROA (TTM)-101.92%
EPS Incl Extra (Annual)$-21.72
Current Ratio (Annual)2.26x
Quick Ratio (Quarterly)0.39x
3-Month Avg Trading Volume0.25M
52-Week Price Return-34.75%
Tangible BV / Share (Quarterly)$0.80
P/S Ratio (Annual)39.95x
Asset Turnover (Annual)0.01x
52-Week High$13.48
Operating Margin (5Y Avg)-10456.68%
EPS Excl Extra (Annual)$-21.72
CapEx CAGR (5Y)-57.33%
Tangible BV CAGR (5Y)-3.99%
26-Week Price Return-74.84%
Quick Ratio (Annual)2.14x
13-Week Price Return-66.23%
Total Debt / Equity (Annual)0.50x
Current Ratio (Quarterly)0.60x
Enterprise Value$27.28M
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)31.34%
Pretax Margin (Annual)-5415.68%
Cash / Share (Annual)$1.37
3-Month Return Std Dev140.47%
ROE (Last FY)-243.62%
Net Interest Coverage (Annual)-43.88x
EPS Basic Excl Extra (Annual)$-21.72
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)1.00x
EPS Incl Extra (TTM)$-3.58
Receivables Turnover (Annual)0.00x
ROI (TTM)-126.66%
P/S Ratio (TTM)39.95x
Pretax Margin (5Y Avg)-8345.71%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.98
Price vs S&P 500 (52W)-62.95%
Year-to-Date Return-70.72%
5-Day Price Return8.45%
EPS Normalized (Annual)$-21.72
ROA (5Y Avg)-76.16%
Net Profit Margin (Annual)-5415.68%
Month-to-Date Return-49.84%
Cash Flow / Share (TTM)$-0.67
EBITD / Share (Annual)$-18.56
Operating Margin (Annual)-5188.32%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-94.73%
LT Debt / Equity (Quarterly)0.10x
EPS Basic Excl Extra (TTM)$-3.58
P/TBV (Quarterly)3.99x
P/B Ratio (Annual)4.61x
Pretax Margin (TTM)-5445.76%
Book Value / Share (Annual)$1.99
Price vs S&P 500 (13W)-75.97%
Beta0.64x
Revenue / Share (TTM)$0.00
ROE (TTM)-221.50%
52-Week Low$0.89
vGradeD
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CVMCel-Sci Corporation | D | — | D | $1.48 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
CEL-SCI Corp is a late-stage biotechnology company developing immunotherapies designed to leverage the immune system against cancer and autoimmune diseases. Its lead program, Multikine, is in Phase 3 clinical trials for head and neck cancer. The company is also advancing its LEAPS technology platform for potential treatment of rheumatoid arthritis.